SAFETY AND PHARMACOKINETICS OF ODM-204 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): OPEN, NONRANDOMISED, UNCONTROLLED, MULTICENTRE, DOSE ESCALATION, FIRST-IN-MAN STUDY WITH A DOSE EXPANSION
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs ODM 204 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Acronyms DUALIDES
- Sponsors Orion
- 12 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 12 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated